Valuation
- Market cap
- 1,600,000
- Revenue TTM
- $27,220,000
- Net income TTM
- $-1,070,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -3.93%
- Debt to equity
- -1.69
Trading
- Volume
- 100
- Avg volume
- —
- Day's range
- $0.08 – $0.08
- Shares out
- 20,000,000
- Stochastic %K
- 0%
- Beta
- 21.16
- Analysts
- —
- Price target
- $11.00
Company profile
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products...
Show more
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 61 2 9667 4411
- Website
- https://www.parnell.com
- Address
- Century Estate, Unit 4 476 Gardeners Road, Alexandria, Australia
Latest news
No headlines yet.
